Nuzenio

Moomoo Axsome Therapeutics

Moomoo Axsome Therapeutics entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 6 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Mon, 10 Aug 2026 11:56:40 GMTAxsome Therapeutics Q2 Loss Widens, Revenue Increases - Moomoo

Sat, 08 Aug 2026 14:51:54 GMTAXSOME THERAPEUTICS Q2 2026 Earnings Preview: Recent $AXSM Insider Trading, Hedge Fund Activity, and More - Moomoo

Sat, 08 Aug 2026 02:10:09 GMTAxsome Therapeutics(AXSM.US) 10% Shareholder Sells US$10.54 Million in Common Stock - Moomoo

Wed, 05 Aug 2026 01:00:25 GMTEarnings Preview: AXSM to Report Financial Results Pre-market on August 10 - Moomoo

Fri, 31 Jul 2026 17:48:00 GMTAxsome Therapeutics Is Maintained at Outperform by Mizuho - Moomoo

Fri, 31 Jul 2026 11:06:17 GMTMizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating - Moomoo

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Moomoo Axsome Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

1 distinct publisher/source names are currently connected to this entity page.